Enanta Closes IPO
In 2013, our Business Law lawyers represented Enanta Pharmaceuticals, in its initial public offering (IPO), which raised $64 million for Enanta's development of new compounds for combination treatment regimens for Hepatitis C. J.P. Morgan and Credit Suisse were the lead underwriters.
Posted on March 26, 2013
RELATED PROFESSIONALS
RELATED SERVICES
INDUSTRIES
PRACTICES
Disclaimer
Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.